Worried about a recession? These cashed-up biotech stocks aren't sweating it.

The gene therapy pioneer may earn approval years after initially teasing investors. It may not be time to celebrate.

The stocks could thrive amid the current uncertainty in the equity market and the economy, Goldman says.

Ark did more selling than buying on April 29, including sale of a South African financial services company's stock.

Wood's Ark Investment Management bought a series of biotech stocks, as it has done repeatedly in recent sessions.

Vertex is one step closer to getting its new pain pill approved, which could substitute for opioids that are highly addictive.

Valuations for biotech stocks have slumped, but could rebound.

Cathie Wood's Ark Investment Management noted that privately held tech stocks are now falling just like publicly held ones.

Ark's flagship Ark Innovation ETF has dropped 31% this year, but it has outperformed the S&P 500 over the last five years.

Apple is asking assemblers to put together 220 million iPhones this year, Bloomberg reported, a tally that largely matches 2021 levels.

Electric-truck manufacturer Nikola, like the broad vehicle industry, has been struggling with supply-chain issues.

DNA-sequencing leader Illumina swung to a loss in Q2 2022. Contributions from Grail didn't help.